What we are studying
The purpose of this study is to investigate the efficacy and safety of Vedolizumab on mucosal healing in subjects with moderate to severe active CD. Vedolizumab has been approved in several regions, including the United States (US), European Union (EU), and Australia for the treatment of adult patients with moderately to severely active CD or Ulcerative Colitis (UC) who have failed conventional treatment, (eg, immunomodulators, corticosteroids, or tumor necrosis factor-alpha (TNF-?) antagonists). The use of vedolizumab in this study is investigational.
This study will look at how effective vedolizumab is at treating CD by viewing the gut using a multiple approach.
$50.00 per visit issued as check at end of study or early withdrawal